Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.55 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24494955 | 1.00 | SLC18A3 (0.55) | SLC18A3PRCPDRD2CCR5TLR9 | |
| SCHEMBL29964208 | 0.87 | SLC18A3 (0.57) | SLC18A3PRCPDRD2TLR9TLR8 | |
| SCHEMBL6247690 | 0.87 | SLC18A3 (0.57) | SLC18A3PRCPDRD2TLR9TLR8 | |
| SCHEMBL24494987 | 0.86 | SLC18A3 (0.50) | SLC18A3DRD2TLR9TLR8TLR7 | |
| SCHEMBL22805198 | 0.84 | SLC18A3 (0.62) | SLC18A3PRCPDRD2TLR9TLR8 | |
| SCHEMBL22805197 | 0.84 | SLC18A3 (0.62) | SLC18A3PRCPDRD2TLR9TLR8 | |
| SCHEMBL22804562 | 0.81 | SLC18A3 (0.49) | SLC18A3DRD2 | |
| SCHEMBL22804564 | 0.81 | SLC18A3 (0.49) | SLC18A3DRD2 | |
| SCHEMBL24681331 | 0.79 | SLC18A3 (0.49) | SLC18A3PRCPDRD2TLR9TLR8 | |
| SCHEMBL6249416 | 0.78 | DRD2 (0.53) | SLC18A3PRCPDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020254572-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-24 | — | — | WO | disclosed |